Market Place
Sourcing Support
FDA approvals rise 49% in 2023; CRISPR’s gene editing therapy sees light of day
In 2022, when the
US Food and Drug Administration (FDA) was reeling under the impact of the
pandem
Top drugs and pharmaceutical companies of 2019 by revenues
Acquisitions and spin-offs dominated headlines in 2019 and the tone was set very early with Bristol-
Top drugs by sales in 2017: Who sold the blockbuster drugs?
The year 2017 was a landmark year for pharmaceutical
industries in the US and Europe, with a sharp i
Biocon now in data integrity net; Chinese money on lookout for generic firms
This week, Phispers brings you more bad news from India’s Biocon, as Health Canada’s cau
Axovant’s hyped Alzheimer’s drug fails trial as Pfizer emulates Axovant; Amneal and Impax in merger talks
This week in Phispers, we bring you news about intepirdine, Axovant’s experimental drug for Al
FDA to share full inspection reports with EU; Difficult week for Teva, J&J, Mylan
This week, Phispers brings you the latest from the world of biosimilars, with Samsung Bioepis tying
Trump tells FDA to fund itself fully through industry fees; Astra’s CEO dumps Teva offer
This
week, Phispers brings you lots of regulatory news from the US, where the Trump
administration h
Can Biocon-Mylan combine overcome its biosimilar program’s European inspection failure?
Last week, PharmaCompass
broke the story about Biocon’s biosimilar program suffering a se
Biocon`s biosimilars program fails European cGMP inspection
India’s pharma stocks have been taking
a beating of late due to compliance-related issues
Top drugs by sales revenue in 2015: Who sold the biggest blockbuster drugs?
The year 2015 has gone down
in history as a record year for mergers and acquisitions in the pharmace
